Available today, the proteoCHIP 12*16 facilitates automated, miniaturized solutions for single cell proteomics applications Today, SCIENION & Cellenion, BICO companies, announced the release of the […]
The partnership will incorporate SCIENION’s CL2 sciREADER system into the PictArray SARS-CoV-2 Serology Test which will shortly begin clinical trials for FDA EUA market clearance […]
CELLINK AB (publ) (“CELLINK”) has entered into an agreement with the owners of Scienion AG (“Scienion”), a German life science company focusing on precision dispensing technologies, to acquire all shares for a purchase price on cash- and debt-free basis of 80 M euros (the “Acquisition”). 40 M euros will be paid in 2,814,032 newly issued shares of series B in CELLINK (the “Consideration Shares”) and the reminder in cash. CELLINK’s Board of Directors will resolve to issue the Consideration Shares in accordance with the authorization from the Annual General Meeting held on December 18, 2019.
CELLINK also contemplates to explore the conditions for raising additional equity through one directed share issue within the limit of CELLINK’s existing authorization to issue shares from the Extraordinary General Meeting held on July 16, 2020.